Cargando…
Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy
PURPOSE: Biliary tract cancer (BTC)is an aggressive disease with a poor prognosis. Most patients are diagnosed at an advanced stage for which curative surgery is not possible and gemcitabine-platinum chemotherapy is the treatment of choice for advanced cases. Several studies had focused on biomarker...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464510/ https://www.ncbi.nlm.nih.gov/pubmed/28443323 http://dx.doi.org/10.22034/APJCP.2017.18.3.857 |
_version_ | 1783242784286703616 |
---|---|
author | Pongmaneratanakul, Skolchart Tanasanvimon, Suebpong Pengsuparp, Thitima Areepium, Nutthada |
author_facet | Pongmaneratanakul, Skolchart Tanasanvimon, Suebpong Pengsuparp, Thitima Areepium, Nutthada |
author_sort | Pongmaneratanakul, Skolchart |
collection | PubMed |
description | PURPOSE: Biliary tract cancer (BTC)is an aggressive disease with a poor prognosis. Most patients are diagnosed at an advanced stage for which curative surgery is not possible and gemcitabine-platinum chemotherapy is the treatment of choice for advanced cases. Several studies had focused on biomarkers to predict response from platinum drugs in lung cancer, but information is limited for BTC. In this study, two single nucleotide polymorphisms (SNPs) in the copper transporter (CTR1) and excision repair cross-complementary group 1 (ERCC1) genes were investigated as predictive biomarkers of objective response to gemcitabine-platinum. METHODS: This cohort study aimed to assess any associations of genetic polymorphisms of these proteins active in drug pathway with treatment response in advanced BTC patients. Twenty six patients were enrolled. DNA was extracted from peripheral blood and genetic polymorphisms were assessed by Taqman allelic discrimination assay. Response was evaluated according to RECIST version 1.1. Results: For the CTR1 polymorphism, GT was the most common genotype (61.5%) followed by GG (34.6%), and TT (3.8%). For the ERCC1 polymorphism, only 2 genotypes were found, CC and CT at 57.7% and 42.3%, respectively. Genetic polymorphisms were not found to be singly associated with response. However, when the 2 genetic polymorphisms were combined, GG/CC showed a higher response rate than the others (p=0.018, Fisher’s Exact Test). CONCLUSION: This is the first study to show an association between CTR1 and ERCC1 polymorphisms and response to gemcitabine-platinum in advanced BTC patients. These polymorphisms might be used as biomarkers to predict response in such cases in the future. |
format | Online Article Text |
id | pubmed-5464510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-54645102017-08-28 Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy Pongmaneratanakul, Skolchart Tanasanvimon, Suebpong Pengsuparp, Thitima Areepium, Nutthada Asian Pac J Cancer Prev Research Article PURPOSE: Biliary tract cancer (BTC)is an aggressive disease with a poor prognosis. Most patients are diagnosed at an advanced stage for which curative surgery is not possible and gemcitabine-platinum chemotherapy is the treatment of choice for advanced cases. Several studies had focused on biomarkers to predict response from platinum drugs in lung cancer, but information is limited for BTC. In this study, two single nucleotide polymorphisms (SNPs) in the copper transporter (CTR1) and excision repair cross-complementary group 1 (ERCC1) genes were investigated as predictive biomarkers of objective response to gemcitabine-platinum. METHODS: This cohort study aimed to assess any associations of genetic polymorphisms of these proteins active in drug pathway with treatment response in advanced BTC patients. Twenty six patients were enrolled. DNA was extracted from peripheral blood and genetic polymorphisms were assessed by Taqman allelic discrimination assay. Response was evaluated according to RECIST version 1.1. Results: For the CTR1 polymorphism, GT was the most common genotype (61.5%) followed by GG (34.6%), and TT (3.8%). For the ERCC1 polymorphism, only 2 genotypes were found, CC and CT at 57.7% and 42.3%, respectively. Genetic polymorphisms were not found to be singly associated with response. However, when the 2 genetic polymorphisms were combined, GG/CC showed a higher response rate than the others (p=0.018, Fisher’s Exact Test). CONCLUSION: This is the first study to show an association between CTR1 and ERCC1 polymorphisms and response to gemcitabine-platinum in advanced BTC patients. These polymorphisms might be used as biomarkers to predict response in such cases in the future. West Asia Organization for Cancer Prevention 2017 /pmc/articles/PMC5464510/ /pubmed/28443323 http://dx.doi.org/10.22034/APJCP.2017.18.3.857 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License |
spellingShingle | Research Article Pongmaneratanakul, Skolchart Tanasanvimon, Suebpong Pengsuparp, Thitima Areepium, Nutthada Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy |
title | Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy |
title_full | Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy |
title_fullStr | Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy |
title_full_unstemmed | Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy |
title_short | Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy |
title_sort | prevalence of ctr1 and ercc1 polymorphisms and response of biliary tract cancer to gemcitabine-platinum chemotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464510/ https://www.ncbi.nlm.nih.gov/pubmed/28443323 http://dx.doi.org/10.22034/APJCP.2017.18.3.857 |
work_keys_str_mv | AT pongmaneratanakulskolchart prevalenceofctr1andercc1polymorphismsandresponseofbiliarytractcancertogemcitabineplatinumchemotherapy AT tanasanvimonsuebpong prevalenceofctr1andercc1polymorphismsandresponseofbiliarytractcancertogemcitabineplatinumchemotherapy AT pengsuparpthitima prevalenceofctr1andercc1polymorphismsandresponseofbiliarytractcancertogemcitabineplatinumchemotherapy AT areepiumnutthada prevalenceofctr1andercc1polymorphismsandresponseofbiliarytractcancertogemcitabineplatinumchemotherapy |